{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:49:25Z","timestamp":1766087365338,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,12,18]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom <jats:italic>EGFR<\/jats:italic>-mutated lung cancer has well stabilised. We present a case of a 73-year-old Japanese woman with no history of smoking. Right pulmonary lower lobectomy, lymph node dissection and segmental resection of the right middle lobe were performed. Additionally, she underwent adjuvant chemotherapy for stage IIIB adenocarcinoma harbouring an <jats:italic>EGFR<\/jats:italic> exon 19 deletion. Afatinib was administered for liver metastases after 15 months. A complete response of metastatic disease was achieved for 2 years. However, afatinib was unavoidably discontinued due to splenectomy for the treatment of idiopathic thrombocytopenic purpura. Although afatinib was not resumed, due to the abscess formation as surgery complication, a drug-free complete response was sustained for over 18 months. The present case suggests that exceptional and durable responses to afatinib can be achieved in individual cases.<\/jats:p>","DOI":"10.1136\/bcr-2018-227383","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T05:26:33Z","timestamp":1548998793000},"page":"e227383","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Long-lasting response to afatinib that persisted after treatment discontinuation in a case of <i>EGFR<\/i>-mutated lung adenocarcinoma"],"prefix":"10.1136","volume":"12","author":[{"given":"Yumie","family":"Yamanaka","sequence":"first","affiliation":[{"name":"Division of Respirology, Department of Internal Medicine, The Jikei Daisan Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Seki","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Internal Medicine, The Jikei Daisan Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Internal Medicine, The Jikei Daisan Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Kuwano","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Internal Medicine, The Jikei University Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"2025082708355080000_12.1.e227383.1","first-page":"383","article-title":"Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials","volume":"5","author":"Passaro","year":"2013","journal-title":"J Thorac Dis"},{"key":"2025082708355080000_12.1.e227383.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30033-X"},{"key":"2025082708355080000_12.1.e227383.3","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.197756"},{"key":"2025082708355080000_12.1.e227383.4","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.109"},{"key":"2025082708355080000_12.1.e227383.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"2025082708355080000_12.1.e227383.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.03.003"},{"key":"2025082708355080000_12.1.e227383.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.01.008"},{"key":"2025082708355080000_12.1.e227383.8","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2147\/OTT.S131756","article-title":"Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report","volume":"10","author":"Jovanovic","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2025082708355080000_12.1.e227383.9","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1097\/JTO.0b013e31822e71f2","article-title":"Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib","volume":"6","author":"Weber","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2025082708355080000_12.1.e227383.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70086-4"},{"key":"2025082708355080000_12.1.e227383.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag0299"},{"key":"2025082708355080000_12.1.e227383.12","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181e8b3c5"},{"key":"2025082708355080000_12.1.e227383.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044238"},{"key":"2025082708355080000_12.1.e227383.14","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2025082708355080000_12.1.e227383.15","doi-asserted-by":"publisher","DOI":"10.1038\/35052073"},{"key":"2025082708355080000_12.1.e227383.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3388"},{"key":"2025082708355080000_12.1.e227383.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"2025082708355080000_12.1.e227383.18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int J Hematol"},{"key":"2025082708355080000_12.1.e227383.19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000449371","article-title":"Achievement of cure with gefitinib in advanced lung adenocarcinoma harboring an activating EGFR Mutation: a case report","volume":"9","author":"Kuwata","year":"2016","journal-title":"Case Rep Oncol"},{"key":"2025082708355080000_12.1.e227383.20","first-page":"375","article-title":"[Long-term survival with complete response by gefitinib treatment followed by noncurative operation for lung cancer]","volume":"67","author":"Fukaya","year":"2014","journal-title":"Kyobu Geka"},{"key":"2025082708355080000_12.1.e227383.21","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.222679"},{"key":"2025082708355080000_12.1.e227383.22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789"},{"key":"2025082708355080000_12.1.e227383.23","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0082"},{"key":"2025082708355080000_12.1.e227383.24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Targeting regulatory T cells","volume":"127","author":"M\u00e9n\u00e9trier-Caux","year":"2010","journal-title":"Int J Cancer"},{"key":"2025082708355080000_12.1.e227383.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-012-0208-y"},{"key":"2025082708355080000_12.1.e227383.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70155-3"},{"key":"2025082708355080000_12.1.e227383.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.01.001"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:35:58Z","timestamp":1756308958000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,31]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/bcr-2018-227383"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227383","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}